IL13 and asthma: Tofacitinib plus dexamethasone produced a greater effect than dexamethasone alone, with an additive effect on the inhibition of IL-13 and IFNγ production from asthma and healthy cells; this additive effect on IL-13 from healthy cells was only apparent at low dexamethasone concentrations (Fig. 3).